Investors & Media : on Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. News Releases Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 Jun 07, 2023 Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023 May 31, 2023 Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH May 19, 2023 Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH May 19, 2023 View all press releases > Recent Events and Presentations May 2023 Company Update May 22, 2023 at 8:30 AM EDT Q1 2023 Intercept Pharmaceuticals Earnings Call Apr 27, 2023 at 8:00 AM EDT Cowen 43rd Annual Healthcare Conference Mar 7, 2023 at 2:10 PM EST Q4 and FY2022 Intercept Pharmaceuticals Earnings Call Mar 2, 2023 at 8:30 AM EST View all events & presentations >
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 Jun 07, 2023
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023 May 31, 2023
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH May 19, 2023
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH May 19, 2023
